Literature DB >> 23836877

Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes.

Vittorio Martinelli1, Gloria Dalla Costa, Bruno Colombo, Dacia Dalla Libera, Alessandro Rubinacci, Massimo Filippi, Roberto Furlan, Giancarlo Comi.   

Abstract

BACKGROUND: Growing evidence suggests that vitamin D deficiency may be one of the most important environmental factors for the development of multiple sclerosis (MS).
OBJECTIVES: The objectives of this paper are to evaluate serum 25-hydroxyvitamin D (25(OH)D) levels in patients with clinically isolated syndromes (CIS) and to examine whether they are related to MS risk.
METHODS: This is a retrospective study of 100 CIS patients hospitalized from 2000 to 2009 at San Raffaele Hospital, Milan, Italy. We evaluated baseline 25(OH)D level as well as clinical, brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data.
RESULTS: A total of 52% of CIS patients had vitamin D deficiency (25(OH)D < 50 nmol/l). During follow-up (median: 7.17 years), 55 patients developed clinically definite MS (CDMS). Patients with very low (< 10th percentile) and low (< 25th percentile) 25(OH)D levels were particularly at risk of CDMS (HRs (95% CIs): 2.12 (0.91-4.96) and 1.61 (0.85-3.03), respectively), while no further reduction in the HRs of disease was observed at high levels of 25(OH)D. This association was even stronger after adjustment for additional risk factors for CDMS development (HRs (95% CIs) for 25(OH)D levels < 10th and 25th percentiles: 3.34 (1.32-8.45) and 2.04 (0.96-4.36), respectively).
CONCLUSION: Low serum vitamin D is associated with increased MS risk in patients with CIS.

Entities:  

Keywords:  Multiple sclerosis; natural history studies; risk factors in epidemiology; vitamin D

Mesh:

Substances:

Year:  2013        PMID: 23836877     DOI: 10.1177/1352458513494959

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  31 in total

1.  Lower 25-Hydroxyvitamin D Is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis.

Authors:  C Wang; Z Zeng; B Wang; S Guo
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

Review 4.  Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis.

Authors:  Wei Zhen Yeh; Melissa Gresle; Vilija Jokubaitis; Jim Stankovich; Anneke van der Walt; Helmut Butzkueven
Journal:  Br J Pharmacol       Date:  2020-08-05       Impact factor: 8.739

Review 5.  Vitamin D status and Parkinson's disease: a systematic review and meta-analysis.

Authors:  Zheng Lv; Huiping Qi; Le Wang; Xiaoxue Fan; Fei Han; Hong Wang; Sheng Bi
Journal:  Neurol Sci       Date:  2014-05-22       Impact factor: 3.307

6.  Vitamin D as an early predictor of multiple sclerosis activity and progression.

Authors:  Alberto Ascherio; Kassandra L Munger; Rick White; Karl Köchert; Kelly Claire Simon; Chris H Polman; Mark S Freedman; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Gilles Edan; Frederik Barkhof; Dirk Pleimes; Ernst-Wilhelm Radü; Rupert Sandbrink; Ludwig Kappos; Christoph Pohl
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

7.  25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis.

Authors:  Gorm Pihl-Jensen; Jette Lautrup Frederiksen
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

8.  Retinal damage and vision loss in African American multiple sclerosis patients.

Authors:  Dorlan J Kimbrough; Elias S Sotirchos; James A Wilson; Omar Al-Louzi; Amy Conger; Darrel Conger; Teresa C Frohman; Shiv Saidha; Ari J Green; Elliot M Frohman; Laura J Balcer; Peter A Calabresi
Journal:  Ann Neurol       Date:  2015-01-13       Impact factor: 10.422

9.  Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod.

Authors:  L Ferre'; F Clarelli; G Sferruzza; M A Rocca; E Mascia; M Radaelli; F Sangalli; G Dalla Costa; L Moiola; M Aboulwafa; F Martinelli Boneschi; G Comi; M Filippi; V Martinelli; F Esposito
Journal:  Neurol Sci       Date:  2018-05-13       Impact factor: 3.307

Review 10.  Association between VDR polymorphisms and multiple sclerosis: systematic review and updated meta-analysis of case-control studies.

Authors:  Yan-Jie Zhang; Li Zhang; Shan-Yu Chen; Guo-Jun Yang; Xiao-Lei Huang; Yu Duan; Li-Juan Yang; Dong-Qing Ye; Jing Wang
Journal:  Neurol Sci       Date:  2017-11-06       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.